GSK CEO performs down position in bid to make use of leucovorin as autism therapy
BOSTON — The CEO of the drugmaker GSK on Wednesday stated the corporate has had a minimal position within the Meals and Drug Administration’s effort to replace the prescribing data of a long-shelved drug in order that it may be used to deal with a situation usually related to autism.
The FDA’s request that the corporate replace the prescribing data for its decades-old remedy leucovorin is “an administrative request,” the CEO, Emma Walmsley, stated throughout a panel dialogue on the STAT Summit.
“We’ve got no industrial curiosity, we’ve no scientific analysis, and we’re not pursuing it,” she added. “So it’s simply the administration at this stage.”
This text is unique to STAT+ subscribers
Unlock this text — plus every day protection and evaluation of the pharma trade — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
